Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

Some patients with limited disease small-cell lung cancer (LD SCLC) are cured after chemo-radiotherapy, but the majority relapse and die from their cancer. Better therapy is needed. Immunotherapy represents the largest advance in cancer therapy in recent years and has demonstrated promising activity in SCLC. In this study we will investigate whether atezolizumab prolongs survival in LD SCLC patients who have undergone chemo-radiotherapy.

NCT Number	NCT03540420
Lead Sponsor	Norwegian University of Science and Technology Collaborators: University Hospital of North Norway, Alesund Hospital, Vestre Viken Hospital Trust, University Hospital, Akershus, Helse Nord-Trøndelag HF, Helse Stavanger HF, Haukeland University Hospital, Sorlandet Hospital HF, Ullevaal University Hospital, Molde Hospital, Helse Fonna, Nordlandssykehuset HF, Volda Hospital, Kristiansund Hospital, Sahlgrenska University Hospital, Skane University Hospital, Karolinska University Hospital, Ôrebro University Hospital, Gävle Hospital, University Hospital, Linkoeping, Odense University Hospital, Aalborg University Hospital, Rigshospitalet, Denmark, National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos, Kantonsspital Winterthur KSW, University Hospital, Basel, Switzerland, Insel Gruppe AG, University Hospital Bern, Kantonsspital Graubünden, Freiburger Spital, Klinik Hirslanden, Zurich, Kantonsspital Olten, Spital STS AG, Ente Ospedaliero Cantonale, Bellinzona, Cantonal Hospital of St. Gallen, St. Olavs Hospital, Oslo University Hospital, Rijnstate Hospital, Isala, Zuyderland Medisch Centrum, The Netherlands Cancer Institute, St. Antonius Hospital, Amphia Hospital, Medisch Spectrum Twente, Erasmus Medical Center
Conditions	Small-cell Lung Cancer
Enrollment	212 participants
Start Date	2018-07-31
Primary Completion	2024-04-01 (estimated)
Study Completion	2027-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-13